about
Injected nanocrystals for targeted drug deliveryPolymorph Impact on the Bioavailability and Stability of Poorly Soluble DrugsA Critical Appraisal of Solubility Enhancement Techniques of PolyphenolsEnergetic Landscape of MDM2-p53 Interactions by Computational Mutagenesis of the MDM2-p53 InteractionA new nano-engineered hierarchical membrane for concurrent removal of surfactant and oil from oil-in-water nanoemulsionPotential applications and human biosafety of nanomaterials used in nanomedicineLayer-by-layer nanoencapsulation of camptothecin with improved activity.Revolving door action of breast cancer resistance protein (BCRP) facilitates or controls the efflux of flavone glucuronides from UGT1A9-overexpressing HeLa cells.Understanding peroral absorption: regulatory aspects and contemporary approaches to tackling solubility and permeability hurdlesBioengineering strategies for designing targeted cancer therapiesFood protein-stabilized nanoemulsions as potential delivery systems for poorly water-soluble drugs: preparation, in vitro characterization, and pharmacokinetics in ratsSummary report of PQRI Workshop on Nanomaterial in Drug Products: current experience and management of potential risks.Preparation and optimization of resveratrol nanosuspensions by antisolvent precipitation using Box-Behnken designEvolution in medicinal chemistry of ursolic acid derivatives as anticancer agentsDevelopment of docetaxel nanocrystals surface modified with transferrin for tumor targetingDevelopment and characterization of a novel nanoemulsion drug-delivery system for potential application in oral delivery of protein drugs.Architectural layer-by-layer assembly of drug nanocapsules with PEGylated polyelectrolytes.Aminoclay-lipid hybrid composite as a novel drug carrier of fenofibrate for the enhancement of drug release and oral absorption.Augmenting drug-carrier compatibility improves tumour nanotherapy efficacy.Iodinin (1,6-dihydroxyphenazine 5,10-dioxide) from Streptosporangium sp. induces apoptosis selectively in myeloid leukemia cell lines and patient cells.Curcumin nanomedicine: a road to cancer therapeuticsPolymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs.Solid-state characterization studies and effect of PEG 20000 and P90G on particle size reduction and stability of complexed glimepiride nanocrystals.Pterodon emarginatus oleoresin-based nanoemulsion as a promising tool for Culex quinquefasciatus (Diptera: Culicidae) control.Nanotherapeutics in the EU: an overview on current state and future directions.Nanoparticles containing insoluble drug for cancer therapy.Glycoprotein CD98 as a receptor for colitis-targeted delivery of nanoparticle.Nanoparticle actuated hollow drug delivery vehicles.A mini review of nanosuspensions development.Enhancement of the oral bioavailability of breviscapine by nanoemulsions drug delivery system.Recent advances in delivery systems and therapeutics of cinnarizine: a poorly water soluble drug with absorption window in stomach.Formulation and stability testing of itraconazole crystalline nanoparticles.Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics.Developing nanocrystals for cancer treatment.Challenges and Strategies in Thermal Processing of Amorphous Solid Dispersions: A ReviewCurrent and emerging lipid-based systems for transdermal drug delivery.Nanoparticulation improves bioavailability of Erlotinib.Microfluidics-mediated assembly of functional nanoparticles for cancer-related pharmaceutical applications.Utilization of nanoemulsions to enhance bioactivity of pharmaceuticals, supplements, and nutraceuticals: Nanoemulsion delivery systems and nanoemulsion excipient systems.Nanocrystal for ocular drug delivery: hope or hype.
P2860
Q26752396-6AB1CF9E-0D33-4F22-B5EE-A9C0E125F162Q26779030-28428DA9-8BFF-48C3-8DC0-7B25163144BAQ26852410-6E59258A-FFFD-4712-B4D1-D1F86CE33A34Q28550874-2B2AE487-F983-4574-9FEE-FC6B7783C6F3Q28834617-7E11FF2A-CEF2-4C7E-9EA5-9E32B842B67FQ32944368-04CF0500-A04D-4314-BCEE-EE6E49F3047AQ33589501-3803DB3F-642C-4D7D-9AF1-14D30A08463FQ33649076-74543A52-0FBD-4CE5-9232-2D63CB62AE8CQ33683206-69D4D915-D7ED-4659-993B-E8B4C66ED1D9Q34194191-EAF4DDA4-3ACE-4A46-AA3B-D0FA09B93552Q34730028-EF024974-0357-42DB-B232-0E0CDCC1ADABQ34871881-B5135C81-05ED-4612-A65E-8FB77CF97060Q35024394-583E8A76-A594-4D28-A0A0-4335F3F6DDDFQ35108020-691F2D6E-7005-4B93-9999-E4AEAAE494AEQ36235151-B4672E5E-6C4F-4FA9-98FD-B596E931A451Q36359394-B66DBFA2-5398-4FDB-9B95-BC4B05D72148Q36375582-5C5295B9-9A16-465D-BD80-D7807588EE3FQ36710243-9FD1B596-442F-4D35-AF5B-9271AB13685FQ36804366-7FA7AEB6-88CC-4896-B864-C7A14D131882Q36806678-DCC7CB5D-4FAF-4F07-848B-B819FED52EF7Q36807261-2E986A07-3DB4-4C2C-8D2B-A66B1777AB28Q37141404-4393AB12-8DA1-4AA1-BDB0-3D1C1F65C076Q37267676-01D36492-606F-42E7-ADB1-673E9E47DD54Q37554839-70909EDF-64B7-47C3-BEA8-23742B629D41Q37601242-84B0BA21-B516-4D1E-A13B-B63B9FA528D9Q37693046-F783FF6E-0FF5-4F96-822C-9FE16D20484AQ37695146-20D96558-D04A-416F-8837-00C253CD2E00Q37970756-B9C6DE82-5094-4B4E-BF03-88B5CD4C0E86Q37970772-AF88F4C7-97DF-4266-8F38-150A9217173EQ38239018-B36A02F7-7713-42D7-9368-0142D6AD078CQ38283583-C7C505F3-85CC-4488-9E08-60EF84A74D96Q38312061-698642F3-D2BF-4917-8E35-6EF670B08C58Q38495022-CE26FBF8-AD03-4DB8-929A-8797C41BDB8DQ38570503-8C50CE35-CBD2-4ED8-971A-8859C83FEEFBQ38573948-A22DB757-1904-4F75-AF43-BD7B5D56CAE5Q38590272-5255B775-DD8E-4447-BA26-582556E04145Q38701944-5B0CE168-5480-47B0-A344-4B232EDB1F82Q38728839-40087641-ECEC-46CA-8861-2B83FA4CA098Q38777505-05B07BEC-AE4E-44C1-86A4-304076FA0AA8Q38831205-282453B8-31C2-4215-A24C-2C119F412725
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Nanonization strategies for poorly water-soluble drugs.
@en
Nanonization strategies for poorly water-soluble drugs.
@nl
type
label
Nanonization strategies for poorly water-soluble drugs.
@en
Nanonization strategies for poorly water-soluble drugs.
@nl
prefLabel
Nanonization strategies for poorly water-soluble drugs.
@en
Nanonization strategies for poorly water-soluble drugs.
@nl
P2093
P1433
P1476
Nanonization strategies for poorly water-soluble drugs
@en
P2093
Chalermchai Khemtong
Huabing Chen
Jinming Gao
Xiangliang Yang
P304
P356
10.1016/J.DRUDIS.2010.02.009
P577
2010-03-03T00:00:00Z